Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses.
In: Clinical Trials Week, 2023-11-14, S. 153-153
serialPeriodical
Zugriff:
A recent study analyzed data from over 170,000 participants in the UK Biobank to evaluate the potential of using metabolomic biomarkers and polygenic risk scores (PRSs) to improve cardiovascular disease (CVD) risk prediction. The study found that incorporating nuclear magnetic resonance (NMR) scores and PRSs into existing risk prediction models significantly enhanced the prediction of first-onset CVD. The addition of both NMR scores and PRSs resulted in the largest improvement in risk prediction, and the study estimated that implementing targeted risk-reclassification with these scores could substantially increase the number of CVD events prevented. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: A cohort study and modelling analyses.
|
---|---|
Zeitschrift: | Clinical Trials Week, 2023-11-14, S. 153-153 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|